A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin

Pharmacogenetics and Genomics

Volumn 23, Issue 10, 2013, Pages 526-534

  Christensen, Mette M H ^a   Pedersen, Rasmus S ^a   Stage, Tore B ^a   Brasch Andersen, Charlotte ^b   Nielsen, Flemming ^a   Damkier, Per ^b   Beck Nielsen, Henning ^b   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

MATE1; metformin; OCT1; OCT2; pharmacogenetics; pharmacokinetics

Indexed keywords

METFORMIN; TOLBUTAMIDE;

ADULT; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; DRUG CLEARANCE; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KIDNEY CLEARANCE; MALE; MATE1 GENE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; OCT2 GENE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; LINKAGE DISEQUILIBRIUM; MALE; METFORMIN; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84885063981     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328364a57d     Document Type: Article

References (39)

1. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348 (Pt 3):607-614.
2. Xia L, Engel K, Zhou M, Wang J. Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells. Am J Physiol Renal Physiol 2007; 292:F682-F690.
3. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979; 16:195-202.
4. Zhou M, Xia L, Engel K, Wang J. Molecular determinants of substrate selectivity of a novel organic cation transporter (PMAT) in the SLC29 family. J Biol Chem 2007; 282:3188-3195.
5. Zhou M, Xia L, Wang J. Metformin transport by a newly cloned protonstimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 2007; 35:1956-1962.
6. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50:81-98.
7. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009; 50:1227-1240.
8. Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 2005; 70:1851-1860.
9. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009; 86:299-306.
10. Koepsell H. Polyspecific organic cation transporters: Their functions and interactions with drugs. Trends Pharmacol Sci 2004; 25:375-381.
11. Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch 2004; 447:666-676.
12. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24:1227-1251.
13. Meyer Zu, Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: Functional characterization, interaction with OCT2, and single nucleotide polymorphisms. Am J Physiol Renal Physiol 2010; 298: F997-F1005.
14. Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011; 21:837-850.
15. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 2009; 19:497-504.
16. Kajiwara M, Terada T, Ogasawara K, Iwano J, Katsura T, Fukatsu A, et al. Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. J Hum Genet 2009; 54: 40-46.
17. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117:1422-1431.
18. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 2009; 20:38-44.
19. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J 2009; 9:242-247.
20. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study. Diabetes 2009; 58:745-749.
21. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 2008; 84:559-562.
22. Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine. Pharmacogenet Genomics 2008; 18:637-645.
23. Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 2013; 93:186-194.
24. Zolk O, Solbach TF, Konig J, Fromm MF. Functional characterization of the human organic cation transporter 2 variant p.270Ala >Ser. Drug Metab Dispos 2009; 37:1312-1318.
25. Kang HJ, Song IS, Shin HJ, Kim WY, Lee CH, Shim JC, et al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos 2007; 35:667-675.
26. Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 2012; 340: 393-403.
27. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002; 12:395-405.
28. Pedersen RS, Christensen MM, Brosen K. Linkage disequilibrium between the CYP2C19.*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population. Eur J Clin Pharmacol 2012; 68: 1463-1464.
29. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83:273-280.
30. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247-254.
31. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
32. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
33. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005; 76:449-462.
34. Fukushima-Uesaka H, Maekawa K, Ozawa S, Komamura K, Ueno K, Shibakawa M, et al. Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab Pharmacokinet 2004; 19:239-244.
35. Choi JH, Wah YS, Kim MJ, Nguyen L, Lee SS, Kang JO, et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics 2009; 19:770-780.
36. Zolk O. Current understanding of the pharmacogenomics of metformin. Clin Pharmacol Ther 2009; 86:595-598.
37. Song IS, Shin HJ, Shin JG. Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes. Xenobiotica 2008; 38:1252-1262.
38. Reznichenko A, Sinkeler SJ, Snieder H, van den Born J, de Borst MH, Damman J, et al. SLC22A2 is associated with tubular creatinine secretion and bias of estimated GFR in renal transplantation. Physiol Genomics 2013; 45:201-209.
39. Savic RM, Yee S, Giacomini KM. Effect of genetic variation in the organic cation transporter 1 and 2 on metformin pharmacokinetics: Nonlinear mixed-effects analysis [abstract]. Clin Pharmacol Ther 2011; 89 (Suppl 1):5.